Reckitt Benckiser (New Zealand) Limited (RBNZ) has been fined $1.08 million today in the Auckland District Court for 10 charges relating to its Nurofen specific pain range products. The products include Nurofen Migraine Pain, Nurofen Tension Headache, Nurofen Period Pain and Nurofen Back Pain.
RBNZ admitted that between 2011 and 2015 its packaging of the products and representations on the nurofen.co.nz website were liable to mislead consumers about the nature, characteristics and suitability of the products.
The product packaging stated that the products “targeted” a particular type of pain, when this was not the case. Each product contained exactly the same active ingredient, 342 mg ibuprofen lysine, and each worked identically to the other products. The website contained a number of statements and a product comparison page which gave the overall impression that RBNZ had created separately formulated products to target and relieve specific types of pain when that was not the case.